Results 81 to 90 of about 282,907 (338)

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Cardiology: hypertrophic cardiomyopathy [PDF]

Clinical Medicine, 2019
Hypertrophic cardiomyopathy (HCM) is defined by the presence of increased left ventricular (LV) wall thickness (for adults, >15 mm in one or more LV myocardial segments) that is not solely explained by abnormal loading conditions (eg hypertension).
openaire   +2 more sources

Identification of a novel titin-cap/telethonin mutation in a Portuguese family with hypertrophic cardiomyopathy

Revista Portuguesa de Cardiologia, 2020
Introduction and objectives: Hypertrophic cardiomyopathy (HCM) is a genetically and phenotypically heterogeneous disease; there is still a large proportion of patients with no identified disease-causing mutation.
Alexandra Toste, Andreas Perrot, Cemil Özcelik, Nuno Cardim   +3 more
doaj   +1 more source

Prognostic role of high‐sensitivity cardiac troponin T in patients with cardiac sarcoidosis: insights from ILLUMINATE‐CS

ESC Heart Failure, Volume 12, Issue 2, Page 869-878, April 2025.
Abstract Aims The prognostic role of high‐sensitivity cardiac troponin T (hs‐cTnT) as a biomarker in patients with cardiac sarcoidosis (CS) has yet to be fully determined, especially when compared with B‐type natriuretic peptide (BNP). Methods and Results In this post‐hoc analysis of the ILLUMINATE‐CS (ILLUstration of the Management and prognosIs of ...
Yuichi Baba, Toru Kubo, Takeru Nabeta, Yuya Matsue, Takeshi Kitai, Yoshihisa Naruse, Tatsunori Taniguchi, Hidekazu Tanaka, Takahiro Okumura, Kenji Yoshioka, Hiroaki Kitaoka   +10 more
wiley   +1 more source

Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin

Science Translational Medicine, 2019
Mutations in MYBPC3 disrupt myosin states of relaxation, and manipulating myosin therapeutically abates the effects of MYBPC3 mutations. Manipulating myosin to curb cardiomyopathy Hypertrophic cardiomyopathy (HCM, thickened heart muscle) is a disease ...
Christopher N Toepfer, H. Wakimoto, Amanda C Garfinkel, B. McDonough, Dan Liao, Jianming Jiang, Angela C. Tai, J. Gorham, I. Lunde, M. Lun, Thomas L Lynch, James W. McNamara, S. Sadayappan, C. Redwood, H. Watkins, J. Seidman, C. Seidman   +16 more
semanticscholar   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Evidence of Declining Mortality Trends for Hypertrophic Cardiomyopathy in the United States and the Impact of the COVID‐19 Pandemic

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Dedicated hypertrophic cardiomyopathy (HCM) center cohorts have reported reductions in HCM‐related deaths, likely due to the introduction of contemporary treatments.
Ahmed Sayed, Barry J. Maron, Ethan J. Rowin, Martin S. Maron   +3 more
doaj   +1 more source

Solving the Riddle of Sudden Cardiac Death in Hypertrophic Cardiomyopathy: The Added Role of Cardiac Magnetic Resonance [PDF]

, 2023
Kamil Stankowski, Stefano Figliozzi, Costanza Lisi, Federica Catapano, Cristina Panico, F. Cannata, Riccardo Mantovani, Antonio Frontera, Renato Bragato, Giulio Stefanini, Lorenzo Monti, Gianluigi Condorelli, Marco Francone   +12 more
openalex   +1 more source

Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy

Circulation, 2018
Background: A better understanding of the factors that contribute to heterogeneous outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically needed to improve patient management and outcomes.
Carolyn Y. Ho, S. Day, E. Ashley, M. Michels, A. Pereira, D. Jacoby, Allison L. Cirino, J. Fox, N. Lakdawala, J. Ware, C. Caleshu, A. Helms, S. Colan, F. Girolami, F. Cecchi, C. Seidman, G. Sajeev, J. Signorovitch, Eric M. Green, I. Olivotto   +19 more
semanticscholar   +1 more source

Explainable artificial intelligence identifies and localizes left ventricular scar in hypertrophic cardiomyopathy using 12-Lead electrocardiogram

Scientific Reports
Left ventricular (LV) scar is a major risk factor for sudden death and heart failure in hypertrophic cardiomyopathy (HCM). LV scar evolves over time and needs longitudinal assessment. Currently, LV scar detection relies on late gadolinium enhancement MRI,
Kasra Nezamabadi, Sanjay Sivalokanathan, Jiwon Lee, Talha Tanriverdi, Meiling Chen, Daiyin Lu, Jadyn Abraham, Neda Sardaripour, Pengyuan Li, Parvin Mousavi, M. Roselle Abraham   +10 more
doaj   +1 more source